Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-arm open-label booster study of dTpa vaccine in healthy Japanese adolescents
jRCT2031260187Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of diphtheria toxoid + tetanus toxoid + acellular pertussis in pertussis, diphtheria and Tetanus, sponsored by GSK. Primary endpoints: Seropositivity for pertussis antigens at 1 month and Seroprotection for diphtheria and tetanus at 1 month. Started Jun 2026; status: active, not recruiting.
02
Drugs
diphtheria toxoid + tetanus toxoid + acellular pertussis
03
Conditions
pertussisdiphtheriaTetanus
Beyond the preview
Go deeper on jRCT2031260187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260187.